自身免疫性甲状腺病患者放免法测定TPOAb及其临床评价

Clinical Evalution of TPOAb results detected ly different assays in patients with autoimmune thyroid disease

为探讨甲状腺过氧化物酶抗体（TPOAb）不同测定方法结果的差异性及其意义，以免疫亲和纯化的TPO制备TPO单克隆抗体及兔抗人TPO抗血清，建立了测定TPOAb的三种方法：液相观抗法RIA、单抗固相RIA及液相竞争RIA。结果7G7单抗腹水稀释400倍的包被最大结合率为389％，12800信时为29．8％，非特异性包被结合率为1．3％。兔抗血清稀释4000倍时结合率在40～50％之间。TPOAb三种不同测定方法的结果呈显著相关（r1.2—0．81；r2．3—0．86；r1.3—0．78；P＜0．001），但单抗固相RIA的阳性率最低，表明单抗固相RIA仅测定针对某一TPO抗原位点的TPO抗体；所建立测定方法为研究不同位点TPOAb在自身免疫性甲状腺病发病中的作用提供了条件。

Thyroid peroxidase (TPO) purified by immunoaffinity chromatography has been used to prepare monoclonal antibidies and rabbit antisera, the TPOmAbs prepared were used to coat polystyrene tube, On the basis, three different assays for TPO antibody (TPOAb) were established, they were liquid dual antibodiesRIA; solid phase RIA and liquid competitive RIA, respectively. The maximal coat binding ratios of asciticfluid of 7G7 TPOmAb diluted by 400 and 12800 times were 38.9% and 29. 8%, respectively. The nonspecific coat binding ratio was 1. 3% ; the ratios of antisera to human TPO diluted by 4000 times were 40%~50%. The results between different assays show significant relationships (r1. 2 = 0. 81, r2.3 = 0. 86,r1. 3 =0. 78;P<0. 001), but the percentages of positive results detected of various assays were slightly diferent, that ofsolid phase RIA was the lowest. These various assays established provided a sound basis for further research the roles of TPOAbs against different epitopes on human TPO in the pathogenesis of AITD.